Anti-CD26 monoclonal antibodies as therapy for diseases associated with cells expressing CD26.

1. A method of treating a patient having a cancer that expresses CD26 comprising administering to said patient a pharmaceutical formulation comprising an anti-CD26 polyclonal antibody, whereby the antibody binds CD26 and arrests cell cycle.

2. The method of claim 1 , further comprising detecting cell cycle arrest.

3. The method according to claim 1 , wherein the antibody was prepared against a recombinantly produced CD26 protein, a CD26 fusion protein, a purified CD26 protein, a partially purified CD26 protein or a naturally occurring CD26 protein.

4. A method of treating a patient having a T-cell cancer that expresses CD26 selected from the group consisting of a T-cell lymphoma, a lymphoblastic lymphoma, an acute lymphoblastic leukemia, a T-cell CD30+ anaplastic large cell lymphoma, a peripheral T-cell lymphoma, a T-cell chronic lymphocytic leukemia, an angioimmunoblastic T-cell lymphoma, an angiocentric T-cell lymphoma, an HTLV-related T-cell leukemia, and an adult T-cell leukemia, comprising administering to said patient a pharmaceutical formulation comprising an anti-CD26 antibody, whereby the anti-CD26 antibody binds CD26 and arrests cell cycle.

5. The method of claim 4 , wherein the anti-CD26 antibody is a monoclonal antibody.

6. The method of claim 5 , wherein the anti-CD26 monoclonal antibody is 1F7.

7. The method according to claim 5 , wherein the monoclonal antibody is humanized.

8. The method of claim 1 , wherein the anti-CD26 antibody is an unconjugated antibody.

9. The method of claim 1 , wherein the cancer is a T-cell cancer, a B-cell cancer, a hematological cancer, a thyroid cancer, a lung adenocarcinoma, a thyroid carcinoma, a melanoma, a breast cancer, an ovarian cancer, a pancreatic cancer, a prostate cancer, a colon cancer, a bladder cancer, a lung cancer, a liver cancer, a stomach cancer, a testicular cancer, a uterine cancer, a brain cancer, a lymphatic cancer, a skin cancer, a bone cancer, a rectal cancer, or a sarcoma.

10. The method of claim 1 , further comprising treating the patient with a second agent, wherein the second agent is a therapeutic polypeptide, a nucleic acid encoding a therapeutic polypeptide, a chemotherapeutic agent, an immunotherapeutic agent, a radiotherapeutic agent, a cytokine, a chemokine, an activating agent, or a biological response modifier.

11. The method of claim 10 , wherein the second agent is administered simultaneously with the anti-CD26 antibody.

12. The method, of claim 10 , wherein the second agent is administered at a different time than the anti-CD26 antibody.

13. The method of claim 1 , wherein the cancer is characterized by tumor formation in said patient.

14. The method of claim 1 , wherein the administering is intravenous, intraarterial, intraperitoneal, intradermal, intratumoral, intramuscular, subcutaneous, intraarthricular, intrathecal, oral, dermal, nasal, buccal, rectal, or vaginal.

15. A method of treating a patient having a cancer comprising inducing CD26 expression in cells of said cancer by contacting the cells with a cytokine, a chemokine, a retinoid, an interferon, a chemotherapeutic agent, an antibody, or an antigen, and administering to said patient a pharmaceutical formulation comprising an anti-CD26 antibody, whereby the anti-CD26 antibody binds CD26 and arrests cell cycle.

16. A method for increasing p21 expression in a CD26+ T-cell lymphoma cell, lung adenocarcinoma cell, thyroid carcinoma cell, melanoma cell, B-cell chronic lymphocytic leukemia cell or B-cell lymphoma cell in vivo comprising contacting the cell with an anti-CD26 antibody, wherein said contacting results in increased p21 expression in the cell in vivo.

17. The method of claim 16 , wherein the T-cell lymphoma is a lymphoblastic lytnphoma, an acute lymphoblastic leukemia, a T-cell CD30+ anaplastic large cell lymphoma, a peripheral T-cell lymphoma, a T-cell chronic lymphocytic leukemia, an angioimmunoblastic T-cell lymphoma, an angiocentric T-cell lymphoma, an HTLV-related T-cell leukemia, or an adult T-cell leukemia.

18. The method of claim 16 , wherein the anti-CD26 antibody is a polyclonal antibody.

19. The method of claim 16 , wherein the anti-CD26 antibody is a monoclonal antibody.

20. The method of claim 19 , wherein the anti-CD26 monoclonal antibody is 1F7.

21. The method according to claim 19 , wherein the monoclonal antibody is humanized.

22. The method of claim 16 , wherein the anti-CD26 antibody is an unconjugated antibody.

23. The method of claim 16 , wherein the anti-CD26 antibody is further attached to a chemotherapeutic agent, a radionuclide, an imaging agent, a toxin, a biological agent, an enzyme inhibitor, or a second antibody.

24. The method of claim 1 , wherein the anti-CD26 antibody is an antibody conjugate.

25. The method of claim 24 , wherein the antibody conjugate comprises an anti-CD26 antibody conjugated to a chemotherapeutic agent, a radionuclide, an imaging agent, a toxin, a biological agent, an enzyme inhibitor, or a second antibody.

26. The method of claim 4 , further comprising detecting cell cycle arrest.

27. The method according to claim 4 , wherein the antibody was prepared against a recombinantly produced CD26 protein, a CD26 fusion protein, a purified CD26 protein, a partially purified CD26 protein or a naturally occurring CD26 protein.

28. The method of claim 4 , wherein the anti-CD26 antibody is an unconjugated antibody.

29. The method of claim 4 , wherein the anti-CD26 antibody is an antibody conjugate.

30. The method of claim 29 , wherein the antibody conjugate comprises an anti-CD26 antibody conjugated to a chemotherapeutic agent, a radionuclide, an imaging agent, a toxin, a biological agent, an enzyme inhibitor, or a second antibody.

31. The method of claim 4 , further comprising treating the patient with a second agent, wherein the second agent is a therapeutic polypeptide, a nucleic acid encoding a therapeutic polypeptide, a chemotherapeutic agent, an immunotherapeutic agent, a radiotherapeutic agent, a cytokine, a chemokine, an activating agent, or a biological response modifier.

32. The method of 31 , claim wherein the second agent is administered simultaneously with the anti-CD26 antibody.

33. The method of claim 31 , wherein the second agent is administered at a different time than the anti-CD26 antibody.

34. The method of claim 4 , wherein the cancer is characterized by tumor formation in said patient.

35. The method of claim 4 , wherein the administering is intravenous, intraarterial, intraperitoneal, intradermal, intratumoral, intramuscular, subcutaneous, intraarthricular, intrathecal, oral, dermal, nasal, buccal, rectal, or vaginal.